Akkuzu Babur, Yilmaz Ismail, Cakmak Ozcan, Ozluoglu Levent N
Department of Otolaryngology Head and Neck Surgery, Baş kent University Faculty of Medicine, Ankara, Turkey.
Auris Nasus Larynx. 2004 Sep;31(3):226-32. doi: 10.1016/j.anl.2004.03.005.
To determine the efficacy of the prostaglandin E1 analogue misoprostol in the treatment of tinnitus in diabetic and/or hypertensive patients.
Double-blind, randomized, placebo-controlled trial.
Tertiary care referral center.
The subjects were 42 patients with hypertension and/or diabetes mellitus who had chronic tinnitus and had experienced tinnitus symptoms for a minimum of 6 months. Twenty-eight patients were randomly assigned to Group I (misoprostol treatment), and 14 patients to the Group II (placebo treatment). Misoprostol therapy was started at 200 microg per day, and was increased 200 microg every 7 days until a dose of 800 microg per day was reached. The same numbers of placebo tablets were given to the control group using the same schedule. Both groups were treated for 1 month. The changes in objective and subjective tinnitus findings from baseline to 1 month were assessed, and the group results were compared. The chi(2)-test, student's t-test and paired-samples t-test were used to analyze the study.
At the completion of treatment, objective assessment showed that tinnitus loudness decreased in 13 (46%) of the 28 patients in the experimental group, whereas this was observed in only two (14%) of the 14 subjects in the placebo group. Subjective tinnitus scoring revealed improvement rates of 29 and 14% for the misoprostol and placebo groups, respectively. When t-test relating to difference between rates were performed, the difference between improvement rate for tinnitus loudness of the experimental group and control group was found to be statistically significant (P = 0.05), but difference between improvement rate based on subjective tinnitus scoring was insignificant (P = 0.22).
Misoprostol is an effective and safe treatment for chronic tinnitus in hypertensive and/or diabetic patients. Our results are encouraging, but further studies of larger series are needed.
确定前列腺素E1类似物米索前列醇治疗糖尿病和/或高血压患者耳鸣的疗效。
双盲、随机、安慰剂对照试验。
三级医疗转诊中心。
研究对象为42例患有慢性耳鸣且耳鸣症状持续至少6个月的高血压和/或糖尿病患者。28例患者被随机分配到第一组(米索前列醇治疗组),14例患者被分配到第二组(安慰剂治疗组)。米索前列醇治疗从每天200微克开始,每7天增加200微克,直至达到每天800微克的剂量。按照相同的给药时间表给对照组服用相同数量的安慰剂片。两组均治疗1个月。评估从基线到1个月客观和主观耳鸣结果的变化,并比较两组结果。采用卡方检验、学生t检验和配对样本t检验分析研究数据。
治疗结束时,客观评估显示,实验组28例患者中有13例(46%)耳鸣响度降低,而安慰剂组14例患者中只有2例(14%)出现这种情况。主观耳鸣评分显示,米索前列醇组和安慰剂组的改善率分别为29%和14%。当对率差进行t检验时,发现实验组和对照组耳鸣响度改善率之间的差异具有统计学意义(P = 0.05),但基于主观耳鸣评分的改善率差异不显著(P = 0.22)。
米索前列醇是治疗高血压和/或糖尿病患者慢性耳鸣的一种有效且安全的方法。我们的结果令人鼓舞,但需要进一步开展更大规模的系列研究。